Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Nacelle Therapeutics Inc
Profile last edited on: 12/27/2006      CAGE: 47ES1      UEI: FEPKCE7F9A97

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2000
First Award
2002
Latest Award
2004
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1500 Hayes Drive
Manhattan, KS 66502
   (785) 532-3901
   jtomich@ksu.edu
   N/A
Location: Single
Congr. District: 01
County: Riley

Public Profile

Nacelle Therapeutics Inc develops and commercializes treatments for cystic fibrosis based on research at the University of Kansas Medical Center. Nacelle Therapeutics research team developed a novel family of transmembrane, ion channel forming peptides that show great promise for cystic fibrosis therapy

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$527,945
Phase II Dollars
$0
Total Awarded
$527,945

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2004 1 NIH $232,945
Project Title: Enhanced Drug Access to Eye Tissues
2002 1 NIH $100,000
Project Title: Synthetic Peptide Modulators of Paracellular Conductance
2002 1 NIH $195,000
Project Title: Channel Replacement Therapy for Cystic Fibrosis

Key People / Management

  Gary Rabold -- President

  John M Tomich

Company News

There are no news available.